BOCA RATON, Fla.– Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company focused on non-invasive and minimally invasive treatments for skin conditions, announced Tuesday that a new study published in Dermatologic Therapy shows the safety and efficacy of its superficial radiotherapy (SRT) technology combined with punch excision to treat keloids.
The single-center retrospective study, titled “Efficacy of Punch Excision Combined With Superficial X-Ray for the Treatment of Keloids,” evaluated 60 patients treated at the Hospital for Skin Diseases in Nanjing, China. The research found that combining punch excision with SRT improved outcomes by enhancing fibroblast apoptosis, producing a synergistic effect. After one year of follow-up, patients reported significant reductions in pain, itching, thickness, and irregularity of keloid scars. No severe adverse reactions were observed.
“This study by Junyou Zheng and colleagues is one of very few to examine punch excision combined with SRT, and it supports existing literature showing the benefits of our SRT technology in preventing keloid recurrence following surgical excision,” said Joe Sardano, chairman and CEO of Sensus Healthcare. “The psychological impact of keloids is not to be underestimated, and this study underscores keloids as a serious medical condition that warrants access to treatment, including combination therapy with SRT. Superficial radiotherapy has a long-standing record of safety, efficacy and patient satisfaction, and we believe studies such as this one will play an important role in shaping payer and policymaker understanding of the significant physical and emotional burden keloids place on patients.”
Brian Berman, M.D., Ph.D., professor of dermatology at the University of Miami Miller School of Medicine and board member of the American Academy of Dermatology, said the findings broaden the scope of safe keloid treatment. “This study extends the safe and effective use of superficial radiation beyond post complete surgical keloid excision to following punch excision keloid debulking, allowing for treatment of multiple and extensive keloids,” Berman said. “This technique was found to be highly statistically significantly effective, by both investigator (VSS) and patient (POSAS) validated scoring scales.”
Keloids, benign skin tumors caused by abnormal scar tissue growth, can lead to chronic pain, itching, and emotional distress. Affecting an estimated 4% to 16% of the population, they occur most frequently among individuals with higher melanin levels, including people of African, Hispanic, and Asian descent. Traditional therapies such as corticosteroid injections, cryotherapy, and laser treatments often have inconsistent outcomes and high recurrence rates, highlighting the need for new approaches like SRT combination therapy.
